Do you want to read an article? Please log in or register.
Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trial
Further Publications
Related content
COMMENTED
Gynecologic Cancer
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from PRIMA/ENGOT-OV26/GOG-3012 trial
★ 0
Recommended and commented by
Prof. Dr Beat Thürlimann, Faculty Member
Ann Oncol
Monk BJ, Barretina-Ginesta MP, Pothuri B, Vergote I, Graybill W, Mirza MR, McCormick CC, Lorusso D, Moore RG, Freyer G, O'Cearbhaill RE, Heitz F, O'Malley DM, Redondo A, Shahin MS, Vulsteke C, Bradley WH, Haslund CA, Chase DM, Pisano C, Holman LL, Pérez MJR, DiSilvestro P, Gaba L, Herzog TJ, Bruchim I, Compton N, Shtessel L, Malinowska IA, González-Martín A
doi: 10.1016/j.annonc.2024.08.2241
Gynecologic Cancer
TP53 mutations and survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: Results of the MITO16A/MaNGO OV-2 study
Int J Cancer
Bignotti E, Simeon V, Ardighieri L, Kuhn E, Marchini S, Califano D, Cecere SC, Bugatti M, Spina A, Scognamiglio G, Paracchini L, Russo D, Arenare L, Tognon G, Lorusso D, Beltrame L, D'Incalci M, Sartori E, De Censi A, Odicino F, Perrone F, Chiodini P, Pignata S
doi: 10.1002/ijc.35203
Gynecologic Cancer
Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial
Lancet Oncol
Oza AM, Lisyanskaya A, Fedenko A, de Melo AC, Shparyk Y, Rakhmatullina I, Bondarenko I, Colombo N, Svintsitskiy V, Biela L, Nechaeva M, Lorusso D, Scambia G, Cibula D, Póka R, Oaknin A, Safra T, Mackowiak-Matejczyk B, Ma L, Thomas D, Lin KK, McLachlan K, Goble S, Kristeleit R
doi: 10.1016/S1470-2045(24)00674-0
Gynecologic Cancer
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial
Ann Oncol
Harter P, Marth C, Mouret-Reynier MA, Cropet C, Lorusso D, Guerra-Alía EM, Matsumoto T, Vergote I, Colombo N, Mäenpää J, Lebreton C, de Gregorio N, Mosconi AM, Rubio-Pérez MJ, Bourgeois H, Fasching PA, Cecere SC, Hardy-Bessard AC, Denschlag D, de Percin S, Hanker L, Favier L, Bauerschlag D, Desauw C, Hillemanns P, Largillier R, Sehouli J, Grenier J, Pujade-Lauraine E, Ray-Coquard I, PAOLA-1/ENGOT-ov25 investigators
doi: 10.1016/j.annonc.2024.10.828
Genitourinary Cancer
Impact of homologous recombination repair/BReast CAncer (BRCA) gene alterations on survival in a real-world setting of metastatic prostate cancer
BJU Int
Wenzel M, Hoeh B, Koll F, Humke C, Fassl A, Reis H, Wild P, Steuber T, Graefen M, Tilki D, Traumann M, Banek S, Chun FKH, Mandel P
doi: 10.1111/bju.16462
Gastrointestinal Cancer
Olaparib as maintenance therapy in non resectable pancreatic adenocarcinoma associated with homologous recombination deficiency profile: A French retrospective multicentric AGEO real-world study
Eur J Cancer
M'Baloula J, Tougeron D, Boilève A, Jeanbert E, Guimbaud R, Ben Abdelghani M, Durand A, Turpin A, Quesada S, Blanc JF, Artru P, Toullec C, Trouilloud I, Pellat A, Touchefeu Y, Pinot J, Caroli-Bosc FX, Taïeb J, Doat S, Bouché O, Védie AL, de Mestier L, Muller M
doi: 10.1016/j.ejca.2024.115051
Breast Cancer
A phase III trial of adjuvant ribociclib plus endocrine therapy vs endocrine therapy alone in patients with HR+/HER2- early breast cancer: final invasive disease-free survival results from the NATALEE trial
Ann Oncol
Hortobagyi GN, Lacko A, Sohn J, Cruz F, Borrego MR, Manikhas A, Park YH, Stroyakovskiy D, Yardley DA, Huang CS, Fasching PA, Crown J, Bardia A, Chia S, Im SA, Martin M, Loi S, Xu B, Hurvitz S, Barrios C, Untch M, Moroose R, Visco F, Parnizari F, Zarate JP, Li Z, Waters S, Chakravartty A, Slamon D
doi: 10.1016/j.annonc.2024.10.015
RECOMMENDED
Breast Cancer
Axillary Surgery in Breast Cancer - Primary Results of the INSEMA Trial
★ 3
Recommended by
Dr Andreas Müller, Faculty Member
N Engl J Med
Reimer T, Stachs A, Veselinovic K, Kühn T, Heil J, Polata S, Marmé F, Müller T, Hildebrandt G, Krug D, Ataseven B, Reitsamer R, Ruth S, Denkert C, Bekes I, Zahm DM, Thill M, Golatta M, Holtschmidt J, Knauer M, Nekljudova V, Loibl S, Gerber B
doi: 10.1056/NEJMoa2412063
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Optimum diagnostic pathway and pathologic confirmation rate of early stage lung cancer: Results from the VIOLET randomised controlled trial
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Lung Cancer
Harris RA, Stokes EA, Batchelor TJP, Internullo E, West D, Jordan S, Nicholson AG, Paul I, Jacobs C, Shackcloth M, Feeney S, Anikin V, McGonigle N, Steyn R, Kalkat M, Stavroulias D, Havinden Williams M, Qadri S, Dobbs K, Zamvar V, Macdonald L, Kaur S, Rogers CA, Lim E, VIOLET trialists
doi: 10.1016/j.lungcan.2024.108070